Beste Uygur

Beste Uygur

Auto-generated profile, based on publicly available information

Beste Uygur

Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Nature
Verified
Journal Article
Closed access
PDF file
MSMariluz Soula
Mariluz Soula
GUGokhan Unlu
Gokhan Unlu
RWRachel Welch
Rachel Welch
ACAleksey Chudnovskiy
Aleksey Chudnovskiy
BUBeste Uygur
Beste Uygur
KBKıvanç Birsoy
Kıvanç Birsoy

31 July 2025 in Cancer Discovery
Verified
Journal Article
Closed access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression. Significance: Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.

11 January 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RTRebecca C. Timson
Rebecca C. Timson
AKArtem Khan
Artem Khan
BUBeste Uygur
Beste Uygur
MSMarwa Saad
Marwa Saad
HYHsi-Wen Yeh
Hsi-Wen Yeh
KBKıvanç Birsoy
Kıvanç Birsoy
Glutathione (GSH) is a highly abundant tripeptide thiol that performs diverse protective and biosynthetic functions in cells. While changes in GSH availability are associated with inborn errors of metabolism, cancer, and neurodegenerative disorders, studying the limiting role of GSH in physiology and disease has been challenging due to its tight regulation. To address this, we generated cell and mouse models that express a bifunctional glutathione-synthesizing enzyme from Streptococcus thermophilus (GshF), which possesses both glutamate-cysteine ligase and glutathione synthase activities. GshF expression allows efficient production of GSH in the cytosol and mitochondria and prevents cell death in response to GSH depletion, but not ferroptosis induction, indicating that GSH is not a limiting factor under lipid peroxidation. CRISPR screens using engineered enzymes further revealed genes required for cell proliferation under cellular and mitochondrial GSH depletion. Among these, we identified the glutamate-cysteine ligase modifier subunit, GCLM, as a requirement for cellular sensitivity to buthionine sulfoximine, a glutathione synthesis inhibitor. Finally, GshF expression in mice is embryonically lethal but sustains postnatal viability when restricted to adulthood. Overall, our work identifies a conditional mouse model to investigate the limiting role of GSH in physiology and disease.

15 September 2026 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
TNToshitaka Nakamura
Toshitaka Nakamura
AIAyaka Inoki
Ayaka Inoki
NDNupur Das
Nupur Das
BCBrandon Chen
Brandon Chen
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy

27 October 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TCTieu Lan Chau
Tieu Lan Chau
ÜBÜmran Borucu
Ümran Borucu
BUBeste Uygur
Beste Uygur
AÖAhmet Göktuğ Özkurt
Ahmet Göktuğ Özkurt
EKEylül Kılıç
Eylül Kılıç
SGSerkan İsMail Göktuna
Serkan İsMail Göktuna
Inhibition of purinergic signaling in cancer has recently received great attention. The purinergic ecto-enzyme CD73 represents a prominent candidate; however its intrinsic role in colorectal cancer (CRC) cells has not been fully investigated. Stable depletion of CD73 expression by using CRISPR/Cas9 in CRC cell lines led to increased cell proliferation, enhanced cell motility and the formation of larger xenograft tumors in mice. These observations may be explained by an exacerbation of the EMT process. In addition, acquired resistance to gefitinib, an EGFR inhibitor, in various CRC models is associated with the loss of CD73 expression. Overexpression of CD73 in CRC cells can revert some of these phenotypes, resulting in slower cell migration, forming smaller xenograft tumors, sensitizing gefitinib response and enhanced apoptosis. Further supporting the tumor suppressive roles of CD73, its overexpression in CRC cells increased vulnerability to cell death induced by multiple agents while its depletion provided protection. Moreover, our bioinformatic analyses with human patient samples supported our in vitro and in vivo results, indicating that the tumor suppressor function of CD73 depends on stromal content and infiltrating immune cell. Collectively, our data strongly reveal that CD73 can function as a tumor suppressor in CRC cells. Therefore, inhibition of CD73 in general may not bring the expected outcome in patient subgroups with poor immune cell infiltration highlighting the need for careful evaluation and personalized treatment based on histopathological features of tumors.

2 December 2025
Verified
Other
Open access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression.Significance:Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.